Phase 3 Studies (EVOLVE-1 & EVOLVE-2) of Galcanezumab in Episodic Migraine: Results of 6-Month Treatment Phase

被引：0
|
作者：
Skljarevski, Vladimir [1 ]
Stauffer, Virginia L. [1 ]
Zhang, Qi [1 ]
Detke, Holland C. [1 ]
Millen, Brian A. [1 ]
Yang, Jyun Yan [1 ]
Selzler, Katherine J. [1 ]
Conley, Robert [1 ,2 ]
Aurora, Sheena K. [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
来源：
CEPHALALGIA | 2017年 / 37卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
PO-01-197
引用
收藏
页码：339 / 340
页数：2
相关论文
共 50 条
  • [21] GALCANEZUMAB EFFECTS IN ADULT PATIENTS WITH EPISODIC OR CHRONIC MIGRAINE ARE PERSISTENT: DATA FROM THREE PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED EVOLVE-1, EVOLVE-2, AND REGAIN STUDIES
    Aurora, S.
    Zhang, Q.
    Stauffer, V.
    CEPHALALGIA, 2018, 38 : 50 - 51
  • [22] Changes in patient functioning and disability: results from two phase 3 double-blind placebo-controlled clinical trials evaluating galcanezumab for episodic migraine prevention (EVOLVE-1 and EVOLVE-2)
    Ford, Janet H.
    Ayer, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Skljarevski, Vladimir
    Aurora, Sheena K.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [23] Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
    Stefanie Förderreuther
    Qi Zhang
    Virginia L. Stauffer
    Sheena K. Aurora
    Miguel J. A. Láinez
    The Journal of Headache and Pain, 2018, 19
  • [24] Preventive effects of galcanezumab in adult patients with episodic or chronic migraine are persistent: data from the phase 3, randomized, double-blind, placebo-controlled EVOLVE-1, EVOLVE-2, and REGAIN studies
    Foerderreuther, Stefanie
    Zhang, Qi
    Stauffer, Virginia L.
    Aurora, Sheena K.
    Lainez, Miguel J. A.
    JOURNAL OF HEADACHE AND PAIN, 2018, 19
  • [25] EFFICACY OF GALCANEZUMAB IN PATIENTS WHO FAILED TO RESPOND TO PREVENTIVES PREVIOUSLY: RESULTS FROM EVOLVE-1, EVOLVE-2 AND REGAIN STUDIES
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S.
    CEPHALALGIA, 2018, 38 : 51 - 52
  • [26] Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from EVOLVE-1, EVOLVE-2 and REGAIN studies
    Zhang, Q.
    Ruff, D. D.
    Pearlman, E. M.
    Govindan, S.
    Aurora, S. K.
    EUROPEAN JOURNAL OF NEUROLOGY, 2018, 25 : 298 - 298
  • [27] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Jessica Ailani
    J. Scott Andrews
    Mallikarjuna Rettiganti
    Robert A. Nicholson
    The Journal of Headache and Pain, 2020, 21
  • [28] Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials)
    Ailani, Jessica
    Andrews, J. Scott
    Rettiganti, Mallikarjuna
    Nicholson, Robert A.
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (01):
  • [29] Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
    Stauffer, Virginia L.
    Dodick, David W.
    Zhang, Qi
    Carter, Jeffrey N.
    Ailani, Jessica
    Conley, Robert R.
    JAMA NEUROLOGY, 2018, 75 (09) : 1080 - 1088
  • [30] Evaluation of Cardiovascular Outcomes in Adult Patients With Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1, EVOLVE-2, and REGAIN Studies
    Oakes, Tina M.
    Kovacs, Richard
    Rosen, Noah
    Doty, Erin
    Kemmer, Phebe
    Aurora, Sheena K.
    Camporeale, Angelo
    HEADACHE, 2020, 60 (01): : 110 - 123
12345